Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages
Authors:
- 17 June 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 158 (1) , 74-83
Abstract
Summary: It has been reported that alveolar macrophages from patients with chronic obstructive pulmonary disease (COPD) display glucocorticoid (Gc) resistance. The Gc sensitivity of inflammatory mediators released by COPD macrophages may vary. The objective of this study was to identify Gc-insensitive inflammatory mediators produced by lipopolysaccharide (LPS)-stimulated alveolar macrophages from COPD patients. LPS-stimulated alveolar macrophages from 15 COPD patients, nine smokers (S) and nine healthy non-smokers (HNS) were stimulated with LPS with or without dexamethasone (100 and 1000 nM). Luminex and enzyme-linked immunosorbent assay were used to measure 23 inflammatory mediators. After LPS stimulation there were lower levels of inflammatory mediators in COPD patients and S compared to HNS. There was no difference between groups for the effects of dexamethasone at either concentration (P > 0·05 for all comparisons). Tumour necrosis factor (TNF)-α, interleukin (IL)-6 and growth-related oncogene (GRO)-α displayed the greatest sensitivity to dexamethasone in COPD patients, while IL-8, granulocyte–macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) were the least sensitive. COPD macrophages have a reduced response to LPS. Gc sensitivity was similar in COPD macrophages compared to controls. We identify some Gc-insensitive cytokines, including GM-CSF, G-CSF and IL-8, that may be involved in the progression of airway inflammation in COPD patients.Keywords
This publication has 34 references indexed in Scilit:
- Inhibition of Lipopolysaccharide-Stimulated Chronic Obstructive Pulmonary Disease Macrophage Inflammatory Gene Expression by Dexamethasone and the p38 Mitogen-Activated Protein Kinase Inhibitor N-cyano-N′-(2-{[8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504)The Journal of Pharmacology and Experimental Therapeutics, 2009
- Inhibitory effect of p38 mitogen‐activated protein kinase inhibitors on cytokine release from human macrophagesBritish Journal of Pharmacology, 2006
- Relative Corticosteroid Insensitivity of Peripheral Blood Mononuclear Cells in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Combinatorial roles of nuclear receptors in inflammation and immunityNature Reviews Immunology, 2005
- Bronchoalveolar lavage in COPD: fluid recovery correlates with the degree of emphysemaEuropean Respiratory Journal, 2005
- Glucocorticoids: Effects on Gene TranscriptionProceedings of the American Thoracic Society, 2004
- Corticosteroid Resistance in Airway DiseaseProceedings of the American Thoracic Society, 2004
- The Nature of Small-Airway Obstruction in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2004
- Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophagesThe FASEB Journal, 2001
- Effects of β2-Agonists and Budesonide on Interleukin-1β and Leukotriene B4Secretion: Studies of Human Monocytes and Alveolar MacrophagesJournal of Asthma, 1998